Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations (2024 - 2025)

Silence Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 17271000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 37.15% year-over-year to 17271000.0; the TTM value through Dec 2025 reached 62271000.0, up 7.94%, while the annual FY2025 figure was 62271000.0, 7.94% up from the prior year.
  • Cash from Operations for Q4 2025 was 17271000.0 at Silence Therapeutics, down from 10900000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5409000.0 in Q2 2024 and bottomed at 27481000.0 in Q4 2024.